<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998088</url>
  </required_header>
  <id_info>
    <org_study_id>ISRCTN96327523</org_study_id>
    <secondary_id>ISRCTN96327523</secondary_id>
    <secondary_id>NTR303</secondary_id>
    <secondary_id>ZonMW945-06-601</secondary_id>
    <secondary_id>Sanquin PPOC-03-002</secondary_id>
    <nct_id>NCT00998088</nct_id>
  </id_info>
  <brief_title>Blood Management in Orthopedic Surgery</brief_title>
  <acronym>TOMaat</acronym>
  <official_title>Optimal Blood Management in Elective Orthopaedic Surgery: The Transfusion &quot;Op Maat&quot; (TOMaat) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin Research &amp; Blood Bank Divisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche BV Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haemonetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanquin Research &amp; Blood Bank Divisions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: to investigate whether the use of several transfusion alternatives (erythropoietin, the
      cell-saver or postoperative drainage and reinfusion systems) in patients undergoing elective
      total knee or hip replacement surgery can lead to allogeneic red blood cell (RBC) saving if a
      restrictive transfusion policy is used.

      Study design: a prospective, double randomized, open, multicenter study in which patients are
      stratified according to their preoperative hemoglobin(Hb) level: stratum I= Hb between 6,1
      and 8,2 mmol/l. These patients are first randomized for Erythropoetin (Epo) or no Epo.

      Stratum II= Hb of 6,1 and lower or 8,2 mmol/l and higher, are not eligible for Epo and thus
      not randomized. Patients in both strata will be randomized for three modalities: a cell saver
      (CS)(to wash, filter and reinfuse autologous shed blood) which is used intra- and
      postoperatively or a postoperative autologous reinfusion drainage system (D) only (to filter
      and reinfuse autologous shed blood) or a restrictive transfusion trigger only (controls).

      Inclusion criteria: All orthopedic patients of 18 years and older being considered for a
      primary or revision total knee- (TKR) or total hip replacement (THR).

      Outcome measures:

      Primary outcome: number of allogeneic red blood cell (RBC) transfusions.

      Secondary outcome: transfusion reactions, rehabilitation time, length of hospital stay
      (days), peri- and post-operative complications during hospitalization, quality of life, cost
      analysis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Power/data analysis: In order to be able to detect a 75% reduction of allogeneic transfusions
      by Epo and a reduction of 30% by autologous (shed blood) transfusions (CS or D) with a power=
      0.9 and an alpha= 0.05, inclusion of 2250 surgery patients (in a worst case scenario of high
      standard deviations) are required for intention-to-treat analysis.

      Knee surgery patients are not randomized for cell saver (no intra-operative blood loss).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of allogeneic red blood cell (RBC) transfusions.</measure>
    <time_frame>up to 3 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peri- and post-operative complications during hospitalization</measure>
    <time_frame>up to 3 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation time</measure>
    <time_frame>in hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb/Ht post-operative</measure>
    <time_frame>at 14 days and 3 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to 3 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion reactions</measure>
    <time_frame>up to 3 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris hip / knee society score (for determination of the mobility of the operated joint)</measure>
    <time_frame>pre-operative and after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>up to 3 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>In hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">2598</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cell saver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>drain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietin and cell saver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietin and drain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>erythropoietin and cell saver</intervention_name>
    <description>weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion</description>
    <arm_group_label>Erythropoietin and cell saver</arm_group_label>
    <other_name>Eprex, Ortho-Biotech</other_name>
    <other_name>Neorecormon, Roche</other_name>
    <other_name>OrthoPAT, Haemonetics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>weekly 40.000 IU s.c. for 4 weeks pre-operatively</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Eprex, Ortho-Biotech</other_name>
    <other_name>Neorecormon, Roche</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OrthoPAT</intervention_name>
    <description>for intra- and post-operative re-infusion of autologous wound blood</description>
    <arm_group_label>cell saver</arm_group_label>
    <other_name>OrthoPAT, Haemonetics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Post-operative drain device</intervention_name>
    <description>For post-operative re-infusion of unwashed wound blood</description>
    <arm_group_label>drain</arm_group_label>
    <other_name>Bellovac-ABT, Astra-Tech, The Netherlands</other_name>
    <other_name>DONOR-drain, Van Straten Medical, The Netherlands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Erythropoietin and OrthoPAT</intervention_name>
    <description>weekly 40.000 IU s.c. for 4 weeks pre-operatively</description>
    <arm_group_label>Erythropoietin and cell saver</arm_group_label>
    <other_name>Eprex, Ortho-Biotech</other_name>
    <other_name>Neorecormon, Roche</other_name>
    <other_name>OrthoPAT, Haemonetics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Erythropoietin and drain device</intervention_name>
    <description>weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period</description>
    <arm_group_label>Erythropoietin and drain</arm_group_label>
    <other_name>Eprex, Ortho-Biotech</other_name>
    <other_name>Neorecormon, Roche</other_name>
    <other_name>Bellovac-ABT, Astra-Tech</other_name>
    <other_name>DONOR-drain, Van Straten Medical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OrthoPAT</intervention_name>
    <description>For intra- and post-operative reinfusion of autologous blood</description>
    <arm_group_label>cell saver</arm_group_label>
    <other_name>OrthoPAT, Haemonetics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Orthopaedic patients of 18 years and older being scheduled for a primary or revision
             total knee (TKR) or total hip replacement (THR).

        Exclusion Criteria:

          -  Patients who refuse homologous blood (e.g.Jehovah's witnesses),

          -  Patients with untreated hypertension (diastolic blood pressure &gt; 95 mm Hg),

          -  Patients with a serious disorder of the coronary artery, peripheral arteries and/or
             carotid arteries,

          -  A recent myocardial infarction or CVA,

          -  Sickle cell anaemia patients,

          -  Malignancy in the operated area,

          -  Pregnancy,

          -  Unsuitability for peri-operative anticoagulation prophylaxis,

          -  Known allergy to erythropoietin,

          -  An infected wound bed,

          -  Revision of an infected prosthesis which is being treated with antibiotics, OR

          -  Patients with difficulty understanding the Dutch language (unable to give informed
             consent or patients who insufficiently control the Dutch language).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Nelissen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Slotervaart Hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Hospital</name>
      <address>
        <city>Gouda</city>
        <state>Zuid Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>October 19, 2009</last_update_submitted>
  <last_update_submitted_qc>October 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr.R.G.H.H.Nelissen</name_title>
    <organization>Leiden University Medical Center</organization>
  </responsible_party>
  <keyword>Blood management</keyword>
  <keyword>Orthopedic surgery</keyword>
  <keyword>elective</keyword>
  <keyword>randomized study</keyword>
  <keyword>adults</keyword>
  <keyword>hip replacement</keyword>
  <keyword>knee replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

